IGF1R and cancer: Inhibition of the IGF1R using inhibitory antibodies results in a considerable reduction in proliferation of tumour cell lines [17] and it has been found to be overactive in cancers including prostate [18], breast [19], colon [20] and gallbladder carcinoma [21].